Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination.

Dobaño C, Santano R, Vidal M, Jiménez A, Jairoce C, Ubillos I, Dosoo D, Aguilar R, Williams NA, Díez-Padrisa N, Ayestaran A, Valim C, Asante KP, Owusu-Agyei S, Lanar D, Chauhan V, Chitnis C, Dutta S, Angov E, Gamain B, Coppel RL, Beeson JG, Reiling L, Gaur D, Cavanagh D, Gyan B, Nhabomba AJ, Campo JJ, Moncunill G.

Front Immunol. 2019 Mar 15;10:439. doi: 10.3389/fimmu.2019.00439. eCollection 2019.

2.

Correlation Between Malaria-Specific Antibody Profiles and Responses to Artemisinin Combination Therapy for Treatment of Uncomplicated Malaria in Western Kenya.

Odhiambo G, Bergmann-Leitner E, Maraka M, Wanjala CNL, Duncan E, Waitumbi J, Andagalu B, Jura WGZO, Dutta S, Angov E, Ogutu BR, Kamau E, Ochiel D.

J Infect Dis. 2019 May 24;219(12):1969-1979. doi: 10.1093/infdis/jiz027.

PMID:
30649381
3.

Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Hall CE, Hagan LM, Bergmann-Leitner E, Tosh DM, Bennett JW, Regules JA, Chuang I, Angov E, Dutta S, Chattopadhyay D, Yadava A.

Infect Immun. 2019 Feb 21;87(3). pii: e00541-18. doi: 10.1128/IAI.00541-18. Print 2019 Mar.

PMID:
30559218
4.

Analysis of factors affecting the variability of a quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens.

Ubillos I, Aguilar R, Sanz H, Jiménez A, Vidal M, Valmaseda A, Dong Y, Gaur D, Chitnis CE, Dutta S, Angov E, Aponte JJ, Campo JJ, Valim C, Harezlak J, Dobaño C.

PLoS One. 2018 Jul 2;13(7):e0199278. doi: 10.1371/journal.pone.0199278. eCollection 2018.

5.

Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1-4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies.

Ubillos I, Jiménez A, Vidal M, Bowyer PW, Gaur D, Dutta S, Gamain B, Coppel R, Chauhan V, Lanar D, Chitnis C, Angov E, Beeson J, Cavanagh D, Campo JJ, Aguilar R, Dobaño C.

Malar J. 2018 Jun 1;17(1):219. doi: 10.1186/s12936-018-2369-3.

6.

Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya.

Weber GE, White MT, Babakhanyan A, Sumba PO, Vulule J, Ely D, John C, Angov E, Lanar D, Dutta S, Narum DL, Horii T, Cowman A, Beeson J, Smith J, Kazura JW, Dent AE.

Sci Rep. 2017 Dec 4;7(1):16821. doi: 10.1038/s41598-017-17084-9.

7.

Assessment of the Combined Effect of Epstein-Barr Virus and Plasmodium falciparum Infections on Endemic Burkitt Lymphoma Using a Multiplex Serological Approach.

Aguilar R, Casabonne D, O'Callaghan-Gordo C, Vidal M, Campo JJ, Mutalima N, Angov E, Dutta S, Gaur D, Chitnis CE, Chauhan V, Michel A, de Sanjosé S, Waterboer T, Kogevinas M, Newton R, Dobaño C.

Front Immunol. 2017 Oct 26;8:1284. doi: 10.3389/fimmu.2017.01284. eCollection 2017.

8.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.

Laurens MB, Kouriba B, Bergmann-Leitner E, Angov E, Coulibaly D, Diarra I, Daou M, Niangaly A, Blackwelder WC, Wu Y, Cohen J, Ballou WR, Vekemans J, Lanar DE, Dutta S, Diggs C, Soisson L, Heppner DG, Doumbo OK, Plowe CV, Thera MA.

PLoS One. 2017 Mar 10;12(3):e0173294. doi: 10.1371/journal.pone.0173294. eCollection 2017.

9.

Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver.

Pichyangkul S, Spring MD, Yongvanitchit K, Kum-Arb U, Limsalakpetch A, Im-Erbsin R, Ubalee R, Vanachayangkul P, Remarque EJ, Angov E, Smith PL, Saunders DL.

PLoS One. 2017 Feb 9;12(2):e0171826. doi: 10.1371/journal.pone.0171826. eCollection 2017.

10.

Seroprevalence of Antibodies against Plasmodium falciparum Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission.

Kusi KA, Bosomprah S, Kyei-Baafour E, Dickson EK, Tornyigah B, Angov E, Dutta S, Dodoo D, Sedegah M, Koram KA.

PLoS One. 2016 Nov 22;11(11):e0167175. doi: 10.1371/journal.pone.0167175. eCollection 2016.

11.

Complement and Antibody-mediated Enhancement of Red Blood Cell Invasion and Growth of Malaria Parasites.

Biryukov S, Angov E, Landmesser ME, Spring MD, Ockenhouse CF, Stoute JA.

EBioMedicine. 2016 Jul;9:207-216. doi: 10.1016/j.ebiom.2016.05.015. Epub 2016 May 14.

12.

Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study.

Spring MD, Pichyangkul S, Lon C, Gosi P, Yongvanichit K, Srichairatanakul U, Limsalakpeth A, Chaisatit C, Chann S, Sriwichai S, Auayapon M, Chaorattanakawee S, Dutta S, Prom S, Meng Chour C, Walsh DS, Angov E, Saunders DL.

Malar J. 2016 Jan 8;15:17. doi: 10.1186/s12936-015-1058-8.

13.

Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort.

Dent AE, Malhotra I, Wang X, Babineau D, Yeo KT, Anderson T, Kimmel RJ, Angov E, Lanar DE, Narum D, Dutta S, Richards J, Beeson JG, Crabb BS, Cowman AF, Horii T, Muchiri E, Mungai PL, King CL, Kazura JW.

Clin Vaccine Immunol. 2015 Dec 9;23(2):104-16. doi: 10.1128/CVI.00452-15. Print 2016 Feb.

14.

Multiple comparisons analysis of serological data from an area of low Plasmodium falciparum transmission.

Rogier E, Wiegand R, Moss D, Priest J, Angov E, Dutta S, Journel I, Jean SE, Mace K, Chang M, Lemoine JF, Udhayakumar V, Barnwell JW.

Malar J. 2015 Nov 4;14:436. doi: 10.1186/s12936-015-0955-1.

15.

Recent advances in recombinant protein-based malaria vaccines.

Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, Theisen M, Biswas S.

Vaccine. 2015 Dec 22;33(52):7433-43. doi: 10.1016/j.vaccine.2015.09.093. Epub 2015 Oct 11. Review.

16.

Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Kumar R, Ray PC, Datta D, Bansal GP, Angov E, Kumar N.

Vaccine. 2015 Sep 22;33(39):5064-71. doi: 10.1016/j.vaccine.2015.08.025. Epub 2015 Aug 20.

17.

Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation.

Kusi KA, Bosomprah S, Dodoo D, Kyei-Baafour E, Dickson EK, Mensah D, Angov E, Dutta S, Sedegah M, Koram KA.

Malar J. 2014 Mar 17;13:103. doi: 10.1186/1475-2875-13-103.

18.
19.

Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen.

Bergmann-Leitner ES, Chaudhury S, Steers NJ, Sabato M, Delvecchio V, Wallqvist AS, Ockenhouse CF, Angov E.

PLoS One. 2013 Aug 16;8(8):e71610. doi: 10.1371/journal.pone.0071610. eCollection 2013.

20.

High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria.

Moncunill G, Mayor A, Jiménez A, Nhabomba A, Casas-Vila N, Puyol L, Campo JJ, Manaca MN, Aguilar R, Pinazo MJ, Almirall M, Soler C, Muñoz J, Bardají A, Angov E, Dutta S, Chitnis CE, Alonso PL, Gascón J, Dobaño C.

PLoS One. 2013 Aug 14;8(8):e73624. doi: 10.1371/journal.pone.0073624. eCollection 2013.

21.

A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Alaro JR, Partridge A, Miura K, Diouf A, Lopez AM, Angov E, Long CA, Burns JM Jr.

Infect Immun. 2013 Oct;81(10):3843-54. doi: 10.1128/IAI.00522-13. Epub 2013 Jul 29.

22.

Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria.

Bergmann-Leitner ES, Hosie H, Trichilo J, Deriso E, Ranallo RT, Alefantis T, Savranskaya T, Grewal P, Ockenhouse CF, Venkatesan MM, Delvecchio VG, Angov E.

Front Immunol. 2013 Jul 4;4:176. doi: 10.3389/fimmu.2013.00176. eCollection 2013.

23.

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.

Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F.

Infect Immun. 2013 Aug;81(8):2882-7. doi: 10.1128/IAI.00461-13. Epub 2013 May 28.

24.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14.

25.

Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure.

Moncunill G, Mayor A, Jiménez A, Nhabomba A, Puyol L, Manaca MN, Barrios D, Cisteró P, Guinovart C, Aguilar R, Bardají A, Pinazo MJ, Angov E, Dutta S, Chitnis CE, Muñoz J, Gascón J, Dobaño C.

PLoS One. 2013;8(2):e55756. doi: 10.1371/journal.pone.0055756. Epub 2013 Feb 21.

26.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD.

Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.

27.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

28.

Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG.

Clin Vaccine Immunol. 2012 Oct;19(10):1633-40. Epub 2012 Aug 15.

29.

Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8.

Alaro JR, Angov E, Lopez AM, Zhou H, Long CA, Burns JM Jr.

Infect Immun. 2012 Jul;80(7):2473-84. doi: 10.1128/IAI.00211-12. Epub 2012 May 14.

30.

Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands.

Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM, Perkins DJ, Zhou G, Githeko A, Yan G.

BMC Infect Dis. 2012 Mar 1;12:50. doi: 10.1186/1471-2334-12-50.

31.

Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.

Mathias DK, Plieskatt JL, Armistead JS, Bethony JM, Abdul-Majid KB, McMillan A, Angov E, Aryee MJ, Zhan B, Gillespie P, Keegan B, Jariwala AR, Rezende W, Bottazzi ME, Scorpio DG, Hotez PJ, Dinglasan RR.

Infect Immun. 2012 Apr;80(4):1606-14. doi: 10.1128/IAI.06212-11. Epub 2012 Feb 6.

32.

Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology.

Hsiang MS, Hwang J, Kunene S, Drakeley C, Kandula D, Novotny J, Parizo J, Jensen T, Tong M, Kemere J, Dlamini S, Moonen B, Angov E, Dutta S, Ockenhouse C, Dorsey G, Greenhouse B.

PLoS One. 2012;7(1):e29550. doi: 10.1371/journal.pone.0029550. Epub 2012 Jan 6.

33.

Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice.

Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner ES, Angov E.

Biotechnol J. 2012 Jan;7(1):133-47. doi: 10.1002/biot.201100331. Epub 2011 Dec 28.

PMID:
22076863
34.

Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.

Campo JJ, Dobaño C, Sacarlal J, Guinovart C, Mayor A, Angov E, Dutta S, Chitnis C, Macete E, Aponte JJ, Alonso PL.

PLoS One. 2011;6(10):e25779. doi: 10.1371/journal.pone.0025779. Epub 2011 Oct 12.

35.

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E.

Vaccine. 2011 Aug 11;29(35):5940-9. doi: 10.1016/j.vaccine.2011.06.053. Epub 2011 Jun 29.

PMID:
21722682
36.

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ.

J Infect Dis. 2011 Jul 1;204(1):9-18. doi: 10.1093/infdis/jir222.

37.

Codon usage: nature's roadmap to expression and folding of proteins.

Angov E.

Biotechnol J. 2011 Jun;6(6):650-9. doi: 10.1002/biot.201000332. Epub 2011 May 12. Review.

38.

Adjustment of codon usage frequencies by codon harmonization improves protein expression and folding.

Angov E, Legler PM, Mease RM.

Methods Mol Biol. 2011;705:1-13. doi: 10.1007/978-1-61737-967-3_1. Review.

PMID:
21125377
39.

Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.

Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E.

PLoS One. 2010 Aug 19;5(8):e12294. doi: 10.1371/journal.pone.0012294.

40.
41.

Molecular vaccines for malaria.

Bruder JT, Angov E, Limbach KJ, Richie TL.

Hum Vaccin. 2010 Jan;6(1):54-77. Epub 2010 Jan 29. Review.

PMID:
20061792
42.

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.

PMID:
19857448
43.

MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.

Bergmann-Leitner ES, Duncan EH, Angov E.

Malar J. 2009 Aug 3;8:183. doi: 10.1186/1475-2875-8-183.

44.

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.

Chowdhury DR, Angov E, Kariuki T, Kumar N.

PLoS One. 2009 Jul 22;4(7):e6352. doi: 10.1371/journal.pone.0006352.

45.

Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.

Bergmann-Leitner ES, Leitner WW, Duncan EH, Savranskaya T, Angov E.

Vaccine. 2009 Sep 18;27(41):5700-8. doi: 10.1016/j.vaccine.2009.06.059. Epub 2009 Jul 2.

PMID:
19576940
46.

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr.

PLoS One. 2009;4(4):e5254. doi: 10.1371/journal.pone.0005254. Epub 2009 Apr 23.

47.

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR; MSP-1 Malaria Vaccine Working Group.

PLoS One. 2009;4(3):e4708. doi: 10.1371/journal.pone.0004708. Epub 2009 Mar 5.

48.

Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.

Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW.

PLoS One. 2008;3(10):e3557. doi: 10.1371/journal.pone.0003557. Epub 2008 Oct 29.

49.

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.

PLoS One. 2008 Jul 30;3(7):e2830. doi: 10.1371/journal.pone.0002830.

50.

Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies.

Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E.

Malar J. 2008 Jul 14;7:129. doi: 10.1186/1475-2875-7-129.

Supplemental Content

Support Center